Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 16 | 2026 | 1545 | 2.380 |
Why?
|
| Genome-Wide Association Study | 15 | 2025 | 1833 | 1.920 |
Why?
|
| Genetic Predisposition to Disease | 16 | 2026 | 3436 | 1.570 |
Why?
|
| Multifactorial Inheritance | 5 | 2025 | 176 | 1.180 |
Why?
|
| Linkage Disequilibrium | 6 | 2025 | 316 | 1.160 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2026 | 750 | 0.890 |
Why?
|
| Periodontitis | 1 | 2022 | 19 | 0.700 |
Why?
|
| Exosomes | 1 | 2022 | 60 | 0.680 |
Why?
|
| Saliva | 1 | 2022 | 125 | 0.670 |
Why?
|
| Smoking | 9 | 2026 | 932 | 0.660 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2025 | 2833 | 0.570 |
Why?
|
| Hepatic Stellate Cells | 4 | 2024 | 30 | 0.540 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2018 | 19 | 0.540 |
Why?
|
| Crohn Disease | 3 | 2025 | 292 | 0.530 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2026 | 357 | 0.510 |
Why?
|
| Insulin Resistance | 1 | 2022 | 690 | 0.490 |
Why?
|
| Inflammation | 3 | 2020 | 1489 | 0.490 |
Why?
|
| Liver | 4 | 2018 | 1796 | 0.480 |
Why?
|
| Fatty Liver | 1 | 2018 | 224 | 0.460 |
Why?
|
| Psoriasis | 2 | 2025 | 48 | 0.450 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2025 | 1459 | 0.440 |
Why?
|
| MicroRNAs | 1 | 2022 | 889 | 0.440 |
Why?
|
| Glioblastoma | 2 | 2026 | 371 | 0.360 |
Why?
|
| CX3C Chemokine Receptor 1 | 2 | 2024 | 14 | 0.360 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2025 | 982 | 0.340 |
Why?
|
| Liver Neoplasms | 4 | 2025 | 1373 | 0.330 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2026 | 2026 | 0.330 |
Why?
|
| RNA-Binding Proteins | 2 | 2026 | 533 | 0.320 |
Why?
|
| Genes, Essential | 1 | 2009 | 39 | 0.300 |
Why?
|
| Humans | 42 | 2026 | 131163 | 0.300 |
Why?
|
| Male | 27 | 2026 | 64957 | 0.280 |
Why?
|
| Prostatic Neoplasms | 4 | 2012 | 1419 | 0.280 |
Why?
|
| Killer Cells, Natural | 2 | 2026 | 355 | 0.270 |
Why?
|
| Mendelian Randomization Analysis | 3 | 2023 | 100 | 0.260 |
Why?
|
| Macrophages | 2 | 2024 | 667 | 0.260 |
Why?
|
| Case-Control Studies | 8 | 2026 | 3359 | 0.250 |
Why?
|
| Middle Aged | 13 | 2026 | 28601 | 0.250 |
Why?
|
| Hexokinase | 1 | 2026 | 21 | 0.240 |
Why?
|
| Risk Factors | 8 | 2026 | 11074 | 0.240 |
Why?
|
| Sirtuin 1 | 1 | 2026 | 55 | 0.230 |
Why?
|
| HLA-C Antigens | 1 | 2025 | 11 | 0.230 |
Why?
|
| Monocytes | 2 | 2018 | 335 | 0.230 |
Why?
|
| Female | 20 | 2026 | 70963 | 0.230 |
Why?
|
| Penetrance | 1 | 2025 | 107 | 0.220 |
Why?
|
| Glycolysis | 1 | 2026 | 174 | 0.220 |
Why?
|
| Aged | 9 | 2026 | 21025 | 0.220 |
Why?
|
| Life Style | 2 | 2025 | 456 | 0.220 |
Why?
|
| Diabetes Mellitus | 2 | 2024 | 889 | 0.220 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2026 | 155 | 0.220 |
Why?
|
| Quantitative Trait Loci | 2 | 2025 | 317 | 0.210 |
Why?
|
| alpha-Synuclein | 1 | 2026 | 143 | 0.210 |
Why?
|
| HLA Antigens | 1 | 2026 | 221 | 0.210 |
Why?
|
| Myositis | 1 | 2025 | 84 | 0.200 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2016 | 236 | 0.200 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2025 | 327 | 0.200 |
Why?
|
| United Kingdom | 4 | 2025 | 267 | 0.200 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2025 | 170 | 0.200 |
Why?
|
| Cell Cycle | 1 | 2026 | 594 | 0.200 |
Why?
|
| Hyperglycemia | 1 | 2025 | 234 | 0.200 |
Why?
|
| Heterozygote | 1 | 2026 | 737 | 0.190 |
Why?
|
| Research Personnel | 1 | 2024 | 139 | 0.190 |
Why?
|
| Population Health | 1 | 2023 | 35 | 0.190 |
Why?
|
| Phenotype | 6 | 2024 | 4497 | 0.190 |
Why?
|
| Amino Acids | 1 | 2025 | 566 | 0.190 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2023 | 77 | 0.180 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2025 | 229 | 0.180 |
Why?
|
| Patient Acuity | 1 | 2022 | 66 | 0.180 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2024 | 359 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 463 | 0.170 |
Why?
|
| Kupffer Cells | 2 | 2018 | 20 | 0.170 |
Why?
|
| Dyspnea | 1 | 2022 | 159 | 0.160 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2020 | 26 | 0.160 |
Why?
|
| Regression Analysis | 1 | 2022 | 761 | 0.160 |
Why?
|
| Brain Neoplasms | 2 | 2026 | 1306 | 0.150 |
Why?
|
| DNA Methylation | 1 | 2026 | 1077 | 0.150 |
Why?
|
| Esophageal Neoplasms | 1 | 2024 | 388 | 0.150 |
Why?
|
| Thoracic Surgery | 1 | 2021 | 163 | 0.150 |
Why?
|
| Body Mass Index | 2 | 2022 | 1717 | 0.140 |
Why?
|
| United States | 5 | 2025 | 12072 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2021 | 336 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 919 | 0.140 |
Why?
|
| Receptors, Cannabinoid | 1 | 2018 | 8 | 0.140 |
Why?
|
| Mice | 6 | 2024 | 18301 | 0.140 |
Why?
|
| Vitamin A | 2 | 2015 | 58 | 0.130 |
Why?
|
| Endocannabinoids | 1 | 2018 | 27 | 0.130 |
Why?
|
| Genetic Testing | 1 | 2025 | 1106 | 0.130 |
Why?
|
| Mice, Knockout | 4 | 2020 | 3819 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2025 | 895 | 0.130 |
Why?
|
| Adult | 8 | 2025 | 31282 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2024 | 972 | 0.120 |
Why?
|
| Kidney Diseases | 1 | 2021 | 477 | 0.120 |
Why?
|
| Glioma | 1 | 2021 | 494 | 0.120 |
Why?
|
| Granulocytes | 1 | 2016 | 69 | 0.120 |
Why?
|
| Hepatocytes | 1 | 2018 | 232 | 0.120 |
Why?
|
| Animals | 8 | 2024 | 33912 | 0.120 |
Why?
|
| Concanavalin A | 1 | 2015 | 15 | 0.120 |
Why?
|
| Diet, High-Fat | 1 | 2018 | 268 | 0.120 |
Why?
|
| Comorbidity | 3 | 2025 | 1595 | 0.110 |
Why?
|
| Immunophenotyping | 1 | 2016 | 332 | 0.110 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2016 | 137 | 0.110 |
Why?
|
| Smokers | 2 | 2026 | 48 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2022 | 1939 | 0.100 |
Why?
|
| Biomarkers | 2 | 2025 | 3385 | 0.100 |
Why?
|
| Cell Differentiation | 2 | 2018 | 1928 | 0.100 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2015 | 157 | 0.100 |
Why?
|
| Interferon-gamma | 2 | 2015 | 544 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2021 | 1168 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 992 | 0.080 |
Why?
|
| Biomarkers, Tumor | 3 | 2026 | 1586 | 0.080 |
Why?
|
| Heart Defects, Congenital | 1 | 2021 | 1889 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2011 | 406 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2026 | 3748 | 0.070 |
Why?
|
| Neoplasms | 2 | 2014 | 3016 | 0.070 |
Why?
|
| Genome, Human | 2 | 2014 | 1321 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2025 | 713 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2026 | 106 | 0.060 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2026 | 99 | 0.060 |
Why?
|
| Genomics | 1 | 2014 | 1621 | 0.060 |
Why?
|
| Oxidative Phosphorylation | 1 | 2026 | 142 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2012 | 1559 | 0.060 |
Why?
|
| CpG Islands | 1 | 2026 | 337 | 0.050 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2026 | 254 | 0.050 |
Why?
|
| Chemokine CX3CL1 | 1 | 2024 | 4 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 4738 | 0.050 |
Why?
|
| Pneumonectomy | 1 | 2026 | 154 | 0.050 |
Why?
|
| Arginase | 1 | 2024 | 34 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2011 | 903 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2026 | 400 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2026 | 521 | 0.050 |
Why?
|
| Cell Communication | 1 | 2024 | 188 | 0.050 |
Why?
|
| North America | 1 | 2024 | 255 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2026 | 480 | 0.050 |
Why?
|
| Exons | 1 | 2025 | 759 | 0.050 |
Why?
|
| Interferon Regulatory Factors | 1 | 2023 | 46 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2025 | 1071 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2024 | 353 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2025 | 1410 | 0.040 |
Why?
|
| Synaptic Transmission | 1 | 2024 | 299 | 0.040 |
Why?
|
| International Agencies | 1 | 2021 | 28 | 0.040 |
Why?
|
| Colitis, Ulcerative | 1 | 2024 | 211 | 0.040 |
Why?
|
| Risk | 1 | 2023 | 726 | 0.040 |
Why?
|
| Metabolomics | 1 | 2025 | 501 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2026 | 713 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2025 | 919 | 0.040 |
Why?
|
| Alleles | 1 | 2026 | 1673 | 0.040 |
Why?
|
| Education | 1 | 2021 | 112 | 0.040 |
Why?
|
| Gene Expression Profiling | 3 | 2012 | 1801 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2023 | 573 | 0.040 |
Why?
|
| Mitochondria | 1 | 2026 | 785 | 0.040 |
Why?
|
| Morbidity | 1 | 2021 | 256 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2025 | 1882 | 0.040 |
Why?
|
| Research Design | 1 | 2024 | 716 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 139 | 0.040 |
Why?
|
| Computational Biology | 1 | 2024 | 862 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2021 | 341 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2021 | 504 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2026 | 2465 | 0.040 |
Why?
|
| Proteins | 1 | 2024 | 1006 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2018 | 95 | 0.030 |
Why?
|
| Spleen | 1 | 2018 | 258 | 0.030 |
Why?
|
| Ethanol | 1 | 2018 | 170 | 0.030 |
Why?
|
| Prognosis | 1 | 2026 | 4886 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2018 | 410 | 0.030 |
Why?
|
| Phagocytes | 1 | 2016 | 25 | 0.030 |
Why?
|
| Mice, Obese | 1 | 2016 | 74 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2021 | 808 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 825 | 0.030 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2015 | 18 | 0.030 |
Why?
|
| Tretinoin | 1 | 2015 | 95 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 112 | 0.030 |
Why?
|
| Length of Stay | 1 | 2021 | 1421 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 2825 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2025 | 6459 | 0.030 |
Why?
|
| Lung | 1 | 2022 | 1535 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 3829 | 0.030 |
Why?
|
| Neurons | 1 | 2024 | 1979 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2015 | 412 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2023 | 5063 | 0.030 |
Why?
|
| Models, Biological | 1 | 2018 | 1371 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2026 | 4686 | 0.020 |
Why?
|
| Cell Survival | 1 | 2015 | 826 | 0.020 |
Why?
|
| Aging | 1 | 2020 | 1242 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2015 | 349 | 0.020 |
Why?
|
| Cell Movement | 1 | 2015 | 876 | 0.020 |
Why?
|
| Carbon Tetrachloride Poisoning | 1 | 2011 | 3 | 0.020 |
Why?
|
| Suppressor of Cytokine Signaling 1 Protein | 1 | 2011 | 10 | 0.020 |
Why?
|
| Poly I-C | 1 | 2011 | 21 | 0.020 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2011 | 25 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 414 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 674 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 4066 | 0.020 |
Why?
|
| Cytokines | 1 | 2016 | 1339 | 0.020 |
Why?
|
| Mutation | 1 | 2024 | 6099 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2026 | 12936 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1797 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2021 | 3147 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 451 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2010 | 483 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2010 | 475 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 1680 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2021 | 17753 | 0.010 |
Why?
|
| Child | 1 | 2021 | 26341 | 0.010 |
Why?
|